DR BENJAMIN TREWIN WELCOMES YOU
Personalised Precision Care
Dr Trewin is a Multiple Sclerosis Neurologist with a warm, professional attitude who places great value on using his specialist experience and emotional astuteness to provide optimal outcomes for all patients.
From simple to complex issues, each patient is treated with care and attention to guarantee the best results.
SPECIALTY SERVICES
NEUROIMMUNOLOGY
Multiple Sclerosis (MS), MOGAD, Neuromyelitis optica (NMO) & Autoimmune encephalitis
Dr Trewin is a subspecialist in autoimmune neurology, he completed his MS & Neuroimmunology Fellowship at RPAH in 2018.
He is completing a PhD at Westmead, focussing on differentiating the clinical and MRI presentation of MOGAD from MS and NMO at onset.
MIGRAINE
Migraine, Cluster headaches & Idiopathic intracranial hypertension (IIH).
Migraine and other forms of headache are a key clinical and research interest of Dr Trewin.
He enjoys achieving outstanding results in an area with many new and highly effective therapies available, where historically there was much pessimism.
MIGRAINE BOTOX & GON BLOCKS
Migraine, Bruxism & Occipital Neuralgia
Dr Trewin offers Botulinum Toxin therapy for headache/migraine and teeth grinding ("Bruxism") and greater and lesser occipital nerve blocks ("GON Block") for occipital neuralgia, which frequently contributes to migraine and cluster headache symptoms.
YOUR TRUSTED NEUROLOGIST
Dr Trewin completed his BAppSc (Exercise & Sport Science & Nutrition) in 2007 and MBBS in 2012 (University of Sydney). He completed his specialty training at St. Vincent’s Hospital, Campbelltown Hospital, Royal Prince Alfred Hospital (Multiple Sclerosis & Neuroimmunology Fellowship) and Concord Repatriation General Hospital.
He is in his final year of a PhD in Neuroimmunology and has published 3 first-author articles in high-impact journals on MOGAD, Neuromyelitis Optica and Autoimmune Encephalitis.
He delivered an oral platform presentation at the Australia and New Zealand Association of Neurology (ANZAN) Annual Scientific Meeting 2023 on MOGAD treatment.
Benjamin has specialist expertise in Multiple Sclerosis and other rarer autoimmune neurological disorders, and has developed extensive experience in managing patients with migraine.
Dr Trewin is an enthusiastic teacher and has taught thousands of training neurologists and doctors throughout his own training, through YouTube @iMeducation101, as a regular examiner at Sydney ClinPrep held for Basic Physician Trainees (BPTs) at St Vincent's Hospital and also via his co-founded MCQ course for the Physicians' Written Exams.
RESEARCH
BAppSc | MBBS | FRACP | PhD Candidate
MS TRIAL SUB-INVESTIGATOR
PASS (Alemtuzumab), ESTEEM (Dimethyl Fumarate), NMO (Eculizumab), PREVANZ (Vitamin D in MS), Biotin (Progressive MS), EXPAND (Siponimod), ENSEMBLE (Ocrelizumab), Visionary-MS (Gold Nanocrystals - Remyelination) [2018 - 2019]
MOGAD, NEUROMYELITIS OPTICA & AUTOIMMUNE ENCEPHALITIS
Trewin BP, Adelstein S, Spies JM, Beadnall HN, Barton J, Ho N, et al. Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Dis. 2020;43:102175.
Trewin BP, Freeman I, Ramanathan S, Irani SR. Immunotherapy in autoimmune encephalitis. Curr Opin Neurol. 2022;35(3):399–414.
Liyanage G, Trewin BP, Dale RC, Ramanathan S, Brilot F, et al. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024; Epub ahead of print. PMID: 38290838.
Rinaldi S, Davies A, Fehmi J, Beadnall HN, Wang J, Hardy TA, ANZ MOG Study Group (Trewin BP et al.) Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurology - Neuroimmunol Neuroinflammation. 2021;8(1):e924.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, PREVENT Study Group (Trewin BP, et al.) Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD. Ann Neurol. 2021;89(6):1088–98
CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION
Trewin B, Tilling J, Levy S. 083 Response to immunosuppressive therapy in cerebral amyloid angiopathy-related inflammation. Journal of Neurology, Neurosurgery and Psychiatry. 2018;89(6):A33-A4
EARLY-ONSET DEMENTIA
Trewin, B, Baskin, J, Levy, S, Sy, J, Tisch, S, ‘CSF1R Mutation-negative Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): Genotypic Heterogeneity in an Important Cause of Early-onset Dementia’ Neurology 2019 [P2.1-024]
MIGRAINE
Day KA, Rettiganti M, Ferguson MB, Stroud CE, Trewin BP, Takeshima T, Kingston WS. Shift from chronic to episodic migraine status and high-to low-frequency episodic migraine status among patients with treatment-resistant migraine in a phase 3 Galcanezumab study. Cephalalgia. 2020;40(1);DP62
CONTACT
